Sandoz (SDZ) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Biosimilar opportunity and growth outlook
13 biosimilars launched in the past 20 years; plan to launch 40–50 over the next 15 years, supported by vertically integrated capabilities.
Nearly $400 billion of biologic sales face loss of exclusivity over the next 10+ years; global biosimilar share is ~20%, with an aspiration to exceed 30%–35% within 10 years.
Management sees competitor numbers per biologic asset declining; entry requires years of development, $100 million, capacity, IP and global commercial reach.
2027 launches include insulins and other European products, four biosimilars in Japan, and U.S. aflibercept in H2; Brazil’s government partnership supports a PDP program.
Enbrel is planned for U.S. launch in 2029; pembrolizumab and other assets are expected to support growth into the 2029–30s. Biosimilar business grew 17% last quarter.
Manufacturing and profitability
Slovenia’s completed large fed-batch facility has 120,000 liters of capacity and is moving through regulatory phases; capacity can be expanded, with more volume shifting to the internal network from 2029.
Target at least 60% of volume from the vertically integrated network by 2035; small fed-batch, large fed-batch and continuous manufacturing enable supply flexibility across yields.
Partner products are less profitable than fully integrated products but generally more profitable than simple small molecules; internal capacity can reduce costs and relieve supply bottlenecks, including for erythropoietin.
Plans include holding SG&A flat while pursuing procurement and operating efficiencies; EBITDA delivery is expected to improve ~1 percentage point annually toward ~30% by 2035.
In-house candidates are planned to rise from two to seven; facilities are in place, while most resulting assets are expected to launch from the mid-2030s.
Market dynamics and strategic focus
German open-house tenders drove biosimilar volume and penetration, with tender pricing determined by competition; volume exceeded forecasts, while sufficient supply is secured for the 2027 financial plan.
Aflibercept own-label opportunity has committed volumes, with value expected from H2 2027 and carryover into 2028; own-label use is described as product-by-product flexibility, not a strategic shift.
GLP-1 launches have begun in Brazil, with a second brand planned following semaglutide INN approval; Canada launch is planned later this year. Early markets remain supply-constrained and demand is expected to exceed supply.
GLP-1 sales are expected to reach billions of dollars, but the value is too early to quantify; the longer-term target to more than double sales value by 2035 excludes GLP-1s.
Value-added medicines are not a focus; management prioritizes biosimilars and generics amid the coming patent-loss opportunity. Transformational M&A is viewed as potentially distracting, with M&A not a priority for the first four to five years after the spin.
Penicillin B2B performance was hurt by Chinese dumping through Indian manufacturers; management expects the impact to wash out by year-end, while retail is described as stable.
Latest events from Sandoz
- Biosimilar growth lifted Q3 sales as FY26 margin guidance rose and sales guidance narrowed.SDZ
Q3 2026 TU - Bio 100 targets over 100 biosimilars by 2040, doubling net sales and margin above 30% by 2035.SDZ
CMD 2026 - Biosimilars drove 5% sales growth and margin expansion, confirming a strong full-year outlook.SDZ
Q2 2026 - Biosimilars drove Q1 2026 growth, offsetting generics decline; guidance reaffirmed.SDZ
Q1 2026 TU - Biosimilars drove record sales and margin expansion, supporting a strong 2026 outlook.SDZ
Q4 2025 - Biosimilars drove 5% sales growth and a margin upgrade, now at 31% of Q3 net sales.SDZ
Q3 2025 TU - Strong pipeline, biosimilar launches, and operational gains drive margin and global growth.SDZ
Sandoz Strategic Review 2024 - Q3 sales up 12% and biosimilars up 32%, prompting raised full-year guidance.SDZ
Q3 2024 - Strong 2023 growth, pipeline expansion, and margin targets drive future biosimilars leadership.SDZ
43rd Annual J.P. Morgan Healthcare Conference 2025 - Biosimilars fueled record sales and margin growth in 2024, supporting a strong outlook for 2025.SDZ
Q4 2024